EP0635498A1 — Quinazoline derivatives and their use as anti-cancer agents
Assigned to AstraZeneca AB · Expires 1995-01-25 · 31y expired
What this patent protects
The invention concerns quinazoline derivatives of the formula I wherein R¹ includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino; R³ is halogeno; n is 1, 2 or 3 and R² includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; or a…
USPTO Abstract
The invention concerns quinazoline derivatives of the formula I wherein R¹ includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino; R³ is halogeno; n is 1, 2 or 3 and R² includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.